The Intersect ENT, Inc. (Nasdaq: XENT) has developed a product family of absorbable, steroid-releasing paranasal sinus implants for patients with chronic sinusitis undergoing paranasal sinus surgery. With the acquisition of Fiagon AG Medical Technologies, Intersect has now taken another important step in expanding the field of use and application of its technology. The parties have agreed a purchase price of approximately 60 million euros.
Legal counsel Intersect ENT, Inc:
Fieldfisher (Germany) LLP: Dr. Andreas Driver (Corporate, Partner), Dr. Cord Willhöft (Life Sciences, Partner), Dr. Stefanie Greifeneder (Commercial IP, Partner, all Munich), Andre Happel (Tax, Partner, Frankfurt), Katharina Hundemer (Life Science, Associate), Iris Lahner (Commercial, Associate, both Munich) Dr. Katja Michel (Corporate, Counsel) and Julian Funck (Tax, Associate, both Frankfurt am Main)
Cooley LLP: Steven Tonsfeldt (Corporate, Partner), Anna Maria Galinska (Corporate, Associate), both Palo Alto, CA, USA
Financial advisor Intersect ENT, Inc:
Goldman Sachs & Co. LLC
Legal adviser Fiagon AG:
Morrison & Foerster LLP: Dr. Dirk Besse (Corporate, Partner), Berlin
Financial advisor Fiagon AG:
Fieldfisher is a dynamically growing international commercial law firm with more than 800 lawyers in Belgium, China, France, Germany, Ireland, Italy, Luxembourg, Spain, UK and USA - Silicon Valley. The firm's particular focus is on the areas of finance, tech, energy & natural resources and life sciences. In addition, the firm advises companies in all sectors of the economy, from start-ups to leading global corporations, as well as the public sector.
Sign up to our email digest
Click to subscribe or manage your email preferences.